Research

  • HALO HT-100 is a delayed-response form of halofuginone hydrobromide, a derivative of a natural compound found in a species of plant. The drug is being developed for Duchenne by Massachusetts-based Halo Therapeutics, LLC
  • Children’s Hospital Oakland Research Institute Dr. Julie Saba. Duchenne is characterized by muscle degeneration resulting in progressive weakness and, ultimately, heart and respiratory failure. Muscle stem cells called satellite cells can foster the regeneration of diseased muscle in DMD, but studies show that satellite cell populations become exhausted over time.
  • Relaxin for Treatment of Duchenne Muscular Dystrophy Investigators: Jeff Chamberlain, PhD; Ron Berenson, MD; and Michael Regnier, PhD. Relaxin is a natural hormone, which has a number of biological effects that may be of benefit in Duchenne Muscular Dystrophy (DMD), including its ability to regenerate muscle, reduce scarring and improve cardiac function.

Partners